An NCI-designated Comprehensive Cancer Center
Howard Jack West

Howard (Jack) West, M.D.

Medical Oncologist
Clinical Expertise
Appointments
Executive Director of Employer Strategy; Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research

Clinical Teams

  • Medical Oncology & Therapeutics Research
"City of Hope has incredible momentum in terms of its clinical program, the range of novel research being conducted, and an innovative approach to how it directs care to patients across a broad geography."
 
Jack West, M.D. is passionate about improving the quality of life for his patients, advancing the research to better treat lung cancer, and raising the level of medical education for patients as well as physicians.
 
Before joining City of Hope, Dr. West directed the Thoracic Oncology Program at Swedish Medical Center in Seattle, where his clinic provided “a collaborative, multidisciplinary strategy” for his patients.
 
A graduate of Princeton University and a Fulbright Scholar, Dr. West received his medical degree from Harvard University and continued his training at Boston's Brigham and Women's Hospital and Seattle's Fred Hutchinson Cancer Center.
 
Dr. West is the founder of the Global Resource for Advancing Cancer Education, a nonprofit organization dedicated to providing timely, free, credible information to patients and caregivers around the world.

Locations

City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

PUBLICATIONS
 
Camidge DR, Kim D-W, Tiseo M, Langer CJ, Ahn M-J, Shaw AT, Huber RM, Hochmair MJ, Lee, DH, Bazhenova LA, Gold KA, Ou S-HI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN. Exploratory analysis of brigatinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials. J Clin Oncol 2018; online ahead of print: DOI: 10.1200/JCO.2017.77.5841
 
West H, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J, Redman M, Kelly K, Gandara DR. Paired phase II studies of erlotinib/ bevacizumab in advanced bronchioloalveolar carcinoma or in never-smokers with advanced non-small-cell lung cancer (NSCLC): SWOG S0635 and S0636 trials. Clin Lung Cancer, 2018;19: 84-92
 
Kim D-W, Tiseo M, Ahn M-J, Reckamp KL, Hansen KH, Kim S-W, Huber RM, West HL, Groen JM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz Arez Rodriguez LG, Smit, EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized multicenter phase II trial. J Clin Oncol 2017, 35: 2490-2498.
 
Wilshire CL, Louie BE, Horton MP, Castiglioni M, Aye RW, Farivar AS, West HL, Gorden JA, Vallières E. Comparison of outcomes for patients with lepidic pulmonary adenocarcinoma defined by 2 staging systems: A North American experience. J Thorac Cardiovasc Surg 2016: 151: 1561-1568.
 
Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Blas B, Puig O, Henschel V, Ou S-HO. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicenter, phase 2 trial. Lancet Oncol 2016, 17: 234-2242.
 
Camidge DR, Berge EM, Doebele RC, Ballas M, Jahan T, Haigentz M, Hoffman D, Spicer J, West H, Lee P, Yang L, Joshi A, Yurasov S, Mita A. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2014; 9: 1532-1539.
 
Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee R-M, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, SH Ou. Safety and efficacy of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014; 15: 1119-1128.
 
Green, MR. West H, Socinski, MA. Impact of the ASCO 2007 Presentation of HOG Lun 01-24/USO-023 on the Prescribing Plans of American Medical Oncologists for Patients with Stage IIIB Non-small Cell Lung Cancer. J Thor Oncol 2009; 4: 983-987.
 
West H, Harpole D, Travis W. Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. CHEST, 2009: 136; 1112-1118.

West HL, Wakelee HA, Perry MC, Belt RJ, Chen R, Obasaju C. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small cell lung cancer: A phase II clinical trial. Annals of Oncology 2009; 20: 850-856.

Chen G, Huynh H, Fehrenbacher L, West H, Lara, PN, Yavorkovsky LL, Russin M, Goldstein D, Gandara D, Lau D. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. Journal of Clinical Oncology, 2009; 27: 1401-1404.
 
Garfield DH, Cadranel J, West HL. Bronchioloalveolar carcinoma: The case for two diseases. Clinical Lung Cancer, 2008: 9: 24-29.

Hirsch F, Varella-Garcia M, Capuzzo F, McCoy J, Bemis L, Xamier A, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar A, Crino L, Gandara D, Franklin W, Bunn Jr P. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology, 18:752-760, 2007.

Nemunaitis J, Meyers T, Senzer N, Cunningham C, West H, Vallieres E, Anthhony S, Vukelja S, Berman, B, Tully H, Pappen BV, Sarmiento S, Arzaga R, Duniho S, Engardt S, Meagher M, Cheever MA. Phase I trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Molecular Therapeutics, 13: 1185-91, 2006.

West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, Gandara DR. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. Journal of Clinical Oncology 24: 1807-1813, 2006.
 
INVITED CHAPTERS / EDITORIALS
 
West H, Dahlberg S. Clinical trials, endpoints, and statistics. Measuring and comparing clinical treatments in practice. JAMA Oncol 2018: in press.
 
West H. Complementary and alternative medicine. JAMA Oncol 2018: 4: 1147.
 
West H. Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs. Ann Transl Med 2017: 5: 371-379.
 
Patel S, West H. Febrile neutropenia. JAMA Oncol 2017, 3: 1751.
 
Pagel J, West H. Chimeric antigen receptor T-cell as cancer therapy. JAMA Oncol 2018, 3: 1595.
 
West H. Do the data on scalp cooling for patients with breast cancer warrant broad adoption? JAMA Oncol 2017: 3: 1147.
 
West H. Bringing adjuvant chemotherapy for resected non-small cell lung cancer into real-world practice: Better late than never? JAMA Oncol 2017; 3: 619.
 
West H. Highlights of recent studies of metastatic non-small cell lung cancer. JAMA Oncol 2017; 3: 159-160.
 
Gupta A, West H. Mucositis (or stomatitis). JAMA Oncol 2016, 2: 1379.
 
West H. Can we define and reach precise goals for precision medicine in cancer care? J Clin Oncol 2016, 34: 3595-3597.
 
Subbiah V, West HL. Jaundice (hyperbilirubinemia) in cancer. JAMA Oncol 2016, 2: 1236.
 
West H, Jin J. Lymph nodes and lymphadenopathy. JAMA Oncol 2016, 2: 971.
 
West H. No solid evidence, only a hollow argument for universal tumor sequencing; Show me the data. JAMA Oncol 2016, 2: 717-718.
 
Subbiah V, West HL. Bone complications in patients with cancer. JAMA Oncol 2016, 695.
 
West H. Young patients with lung cancer – an understudied population. JAMA Oncol 2016, 2: 321.
 
 
EDITORIALS AND LETTERS
 
West H. EGFR inhibitors fight BAC. Signal; 1: 18-20, 2005.
 
West H, Garfield DH. Bronchioloalveolar carcinoma: not as easy as “BAC”. J Thor Oncol 4: 1047-1048, 2009.
 
West H. The role for surgery in stage III non–small-cell lung cancer: Can we reliably select the right patients?  Clin Lung Cancer 10: 314-316, 2009.
 
Stinchecombe TE, West HL. Maintenance therapy in non-small-cell lung cancer. Lancet 374: 1398-1400, 2009.
 
West H. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: Incremental benefit, debatable value. J Clin Oncol 29: 1095-1098, 2011.
 
West H, Camidge DR. Have mutation, will travel: Utilizing online patient communities and new trial strategies to optimize clinical research in the era of molecularly diverse oncology. J Thor Oncol  7: 482-484, 2012.
 
West H. Practicing in partnership with Dr. Google: The growing effect of social media in oncology practice and research. Oncologist 18: 780-782, 2013.
 
West H. Patients with advanced non-small-cell lung cancer and marginal performance status: Walking the tight rope toward improved survival. J Clin Oncol 31: 2841-2843, 2013.
 
West H. Afatinib for advanced mutation NSCLC: New hope or new Coke? J Commun Supp Oncol 12: 115-117, 2014.
 
West H. The failure of figitumumab: the danger of taking shortcuts in drug development. Ann Oncol 26: 447-448, 2015.
 
West H. Individualizing adjuvant therapy for early stage non-small cell lung cancer: we see the destination, but we don’t yet know the route. J Thorac Dis 7: 235-237; 2015.
 
West H. Immune checkpoint inhibitors. JAMA Oncol 1: 115, 2015
 
West H. Malignant pleural effusions. JAMA Oncol 1: 260, 2015.
 
West H. Circulating tumor cells. JAMA Oncol 1: 394, 2015.
 
West H, Jin J. Neoadjuvant therapy. JAMA Oncol 1: 550, 2015.
 
West H, Jin J. Adjuvant therapy. JAMA Oncol 1: 698, 2015.
 
West H & Jin J. The evolution of a cancer. JAMA Onc 1: 850, 2015.
 
West H, Jin J. Performance status in cancer patients. JAMA Onc 1: 998, 2015.
 
West H, Jin J.Transarterial chemoembolization. JAMA Oncol 1: 1178, 2015.
 
West H. The slippery slope of broadening eligibility and weak endpoints: defending the oligo in oligometastatic non-small cell lung cancer. JAMA Oncol 1: 1219-1220, 2015.
 
West H. Balancing benefit, risk, and time to new cancer therapies. JAMA Oncol 2016, 2: 122.
 
West H, Jin J. Portacaths. JAMA Oncol 2: 152, 2016.
 
Bates G, Taub R, est H. Fertility and cancer treatment. JAMA Oncol 2: 284, 20156.
 
West H. Young patients with lung cancer – an understudied population. JAMA Oncol 2: 321, 2016.
 
Subbiah V, West HL. Bone complications in patients with cancer. JAMA Oncol 2: 695, 2016.    
             
West H. No solid evidence, only a hollow argument for universal tumor sequencing; Show me the data. JAMA Oncol 2: 717-718, 2016.
 
West H, Jin J. Lymph nodes and lymphadenopathy. JAMA Oncol 2: 971, 2016.
 
Subbiah V, West HL. Jaundice (hyperbilirubinemia) in cancer. JAMA Oncol 2: 1236, 2016.
 
West H. Can we define and reach precise goals for precision medicine in cancer care? J Clin Oncol 34: 3595-3597, 2016.
 
Gupta A, West H. Mucositis (or stomatitis). JAMA Oncol 2: 1379, 2016.
 
West H. Highlights of recent studies of metastatic non-small cell lung cancer. JAMA Oncol 3: 159-160, 2017.
 
West H. Bringing adjuvant chemotherapy for resected non-small cell lung canceinto real-world practice: Better late than never? JAMA Oncol 3: 619, 2017.
 
West H. Do the data on scalp cooling for patients with breast cancer warrant broad adoption? JAMA Oncol 3: 1147, 2017.
 
Pagel J, West H. Chimeric antigen receptor T-cell as cancer therapy. JAMA Oncol 3: 1595, 2017.
 
Patel S, West H. Febrile neutropenia. JAMA Oncol 3: 1751, 2017.
 
West H. Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs. Ann Transl Med 5: 371-379, 2017.
 
West H. Complementary and alternative medicine. JAMA Oncol 4: 1147, 2018.
 
Gupta A, Wolfe HR, est H. I have neutropenia – what do I need to know? JAMA Oncol 4: 1307, 2018.
 
West H. Redefining the value proposition of precision oncology: can we integrate genomic testing without overselling it? JAMA Oncol 4: 1423-1424, 2018.
 
West H, Dahlberg S. Clinical trials, endpoints, and statistics. Measuring and comparing clinical treatments in practice. JAMA Oncol 4: 1798, 2018.
 
Gyawali B, West H. Plasma vs tissue next-generation sequencing in non-small cell lung cancer – either, both, or neither? JAMA Oncol 2018 doi:10.1001/jamaoncol.2018.4304 (online ahead of print).
 
BOOK CHAPTERS
 
Mark GP, Schwartz, DH, Hernandez L, West HL, Hoebel BG. Application of brain microdialysis to the study of motivation and conditioning: Measurements of dopamine and serotonin in freely-behaving rats. In: TE Robinson & JP Justice, Eds.: Microdialysis in Neuroscience. Amsterdam: Elsevier Science Publishing, pp. 131-136, 1993.
 
West HL, Rebeck GW, Growdon JH, Hyman BT. Apolipoprotein E4 affects neuropathology but not clinical progression in Alzheimer’s disease. In: K Iqbal, JA Mortimer, B Winblad, & HM Wisniewski, Eds., Research Advances in Alzheimer’s disease and Related Disorders. Chichester, UK: John Wiley & Sons, pp. 363-370, 1995.
 
Hyman, BT, Sodhi, P, Harr SD, West HL, Simonian NA, Rebeck GW, Mui S, Isla-Gomez T. The paradox of neurofibrillary tangles and senile plaques in Alzheimer’s disease. In:  K Iqbal, JA Mortimer, B Winblad, & HM Wisniewski, Eds., Research Advances in Alzheimer’s disease and Related Disorders. Chichester, UK: John Wiley & Sons, pp. 453-460, 1995.
 
Brendel D, West H, Hyman S. Hallucinogens. In: D Roberts & L Friedman, Eds., Source Book of Substance Abuse and Addiction. Baltimore, MD: Williams & Wilkins, pp. 217-230, 1995.
 
West H, Kelly K. Pleural malignancies and benign neoplasms of the lung.  In ME Hanley & C Welsh, Eds., Current Medical Diagnosis and Treatment in Pulmonary Medicine. New York: Lange Medical Books/McGraw Hill, pp. 433-439, 2003.
 
West H. Incorporation of novel therapies into the management of locally advanced NSCLC. In R Govindan, Ed., Locally Advanced Non-Small-Cell Lung Cancer. New York: CMP Healthcare Media, pp. 95-105, 2004.
 
West H, Garfield D.  Bronchioloalveolar Carcinoma: New insights in epidemiology, pathology, and novel strategies. Update chapter for HI Pass, JB Mitchell, DH Johnson, AT Turrisi, & J Minna (Eds.), Lung Cancer: Principles and Practice.  Philadelphia: Lippincott, Williams, & Wilkins. Supplement, pp 1-12, 2004.
 
West H. Management of Multi-Focal Bronchioloalveolar Carcinoma (BAC), In Lung Cancer, 4th Ed (Roth JA, Cox JD, Hong WK, Chang JY, Blackmon S, & Tsao A, eds.) Wiley Oxford, pp 158-175, 2013.
In The News
An Expert's Voice
Howard Jack West

Webinar recap: Managing lung cancer in patients through the pandemic